Plozalizumab
Based on 1 Customer Validation
Plozalizumab (MLN-1202) is a humanized anti-CCR2 IgG1 monoclonal antibody. Plozalizumab blocks the recruitment of myeloid cells to the tumor microenvironment by inhibiting the CCL2/CCR2 axis. In addition, Plozalizumab also ameliorates synovial inflammation in rheumatoid arthritis. Plozalizumab can be used in the research of malignant melanoma and bone metastasis-related cancers. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001).
For research use only. We do not sell to patients.
- Purity: 99.53%
- CAS No.: 1610761-46-0
- Molecular Weight:146.08 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Human IgG1 kappa
Human
|
CCR2 |
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG1 kappa
ELISA, FACS, Functional assay
-
Flow cytometric analysis of 1.5*106 THP-1 cells labeling Plozalizumab (HY-P99781, red). Cells were fixed with 4% paraformaldehyde. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa (HY-P99001, blue) was used as the isotype control.
Chemical Information
-
CAS No. 1610761-46-0
-
Appearance Liquid
-
Molecular Weight 146.08 kDa
-
Color Colorless to light yellow
-
SMILES
[Plozalizumab]
-
Synonyms
MLN-1202
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
-
Data Sheet (257 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Piehl F, et al. Current and emerging disease-modulatory therapies and treatment targets for multiple sclerosis. J Intern Med. 2021;289(6):771-791. [Content Brief]
[2]. Jahchan NS, et al. Tuning the Tumor Myeloid Microenvironment to Fight Cancer. Front Immunol. 2019;10:1611. Published 2019 Jul 25. [Content Brief]
[3]. Majety M, et al. A drug development perspective on targeting tumor-associated myeloid cells. FEBS J. 2018;285(4):763-776. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)